Healthcare | May 09, 2022
Strengthening the access to rare disease treatment in India
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Under the agreement, Univar Solutions customers in Brazil and Mexico will have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
Submissions for Ruminant Well-Being Awards and Gustav Rosenberger Memorial Fund grant open now
If the government feels that the industry is not complying with the uniform code, it will consider making it a statutory code
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Subscribe To Our Newsletter & Stay Updated
